Uric acid reducing composition and preparation thereof
A uric acid-lowering technology and composition, applied in the field of uric acid-lowering composition and its preparations, can solve problems such as neutropenia, patient pain, and threats to health, and achieve the goal of reducing blood uric acid levels, good uric acid-lowering effects, and promoting uric acid excretion Effect
Patent Information
- Authority / Receiving Office
- CN · China
- Current Assignee / Owner
- Publication Date
- 2016-03-09
Smart Images
Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] The invention relates to the technical field of health products, in particular to a uric acid-lowering composition and its preparation. Background technique
[0002] With the improvement of people's living standards and changes in eating habits, the incidence of hyperuricemia and gout in my country has been increasing year by year in recent years. Hyperuricemia is a disease in which blood uric acid exceeds the normal value due to purine metabolism disorder and / or uric acid excretion disorder, and it does not show any symptoms clinically. When the human body is in the condition of hyperuricemia for a long time, uric acid is precipitated in the joints, soft tissues, cartilage and kidneys in the form of sodium salt, causing human organ and tissue lesions, leading to gout, and causing serious complications, including gouty Arthritis, gouty nephropathy, gouty kidney stones, gouty heart disease, gouty hypertension, etc., patients have joint pain, renal coli...
Examples
Embodiment 1
[0044] Embodiment 1 uric acid lowering test
[0045] 1. Materials and methods
[0046] Experimental animals: male SD rats of SPF grade, weighing 180±10 g, were provided by Guangdong Medical Experimental Animal Center (permit number: SYXK (Guangdong) 2013-0002).
[0047] Test group: The test is divided into blank control group, model group, benzbromarone control group, first control group, second control group, third control group, first test group, and second test group, with 10 animals in each group rat.
[0048] Administration route: intragastric administration (consistent with the intended clinical administration route for humans). Administration volume: 10ml / kg. Dosing time: Gastrointestinal administration of therapeutic drugs at the same time as modeling, and intragastric administration according to body weight once a day in the morning. Administration period: continuous administration for 28 days.
[0049] Drug preparation: ready-to-use and ready-to-use, weigh a cer...
Embodiment 2
[0073] Embodiment 2 lowering uric acid test
[0074] 1. Materials and methods
[0075] Experimental animals: male SD rats of SPF grade, weighing 180±10 g, were provided by Guangdong Medical Experimental Animal Center (permit number: SYXK (Guangdong) 2013-0002).
[0076] Test group: The test is divided into blank control group, model group, benzbromarone control group, first control group, second control group, third control group, first test group, and second test group, with 10 animals in each group rat.
[0077] Administration route: intragastric administration (consistent with the intended clinical administration route for humans). Administration volume: 10ml / kg. Dosing time: Gastrointestinal administration of therapeutic drugs at the same time as modeling, and intragastric administration according to body weight once a day in the morning. Administration period: continuous administration for 28 days.
[0078] Drug preparation: ready-to-use and ready-to-use, weigh a cer...
Embodiment 3
[0104] Embodiment 3 lowering uric acid test
[0105] 1. Materials and methods
[0106] Experimental animals: male SD rats of SPF grade, weighing 180±10 g, were provided by Guangdong Medical Experimental Animal Center (permit number: SYXK (Guangdong) 2013-0002).
[0107] Test groups: The test was divided into blank control group, model group, benzbromarone control group, first control group to sixth control group, first test group to sixth test group, with 10 rats in each group.
[0108] Administration route: intragastric administration (consistent with the intended clinical administration route for humans). Administration volume: 1.5ml / 100g. Dosing time: Gastrointestinal administration of therapeutic drugs at the same time as modeling, and intragastric administration according to body weight once a day in the morning. Administration period: continuous administration for 28 days.
[0109] Drug preparation: ready-to-use and ready-to-use, weigh a certain amount of the test su...